Medtronic nets approval in Japan for defibrillator leads

Medtronic has received Japanese regulatory approval for its Sprint QuattroTM (Model 6944 and 6947) steroid-eluting right ventricular lead used with implantable cardioverter-defibrillators (ICDs) that detect and treat rapid and potentially lethal heart rhythms.

Medtronic said its Sprint Quattro 6947, with bipolar sensing and dual coil defibrillation, is Japan’s first 8.6 French defibrillation lead to feature screw-in fixation. Screw-in fixation offers flexibility in securing the ICD lead in various right ventricle locations.

The Sprint Quattro 6947 Screw-In ICD lead is used with various ICD and cardiac resynchronization therapy (CRT) devices, Medtronic said.
The company has now commercially launched its product in Japan.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.